FRAZIER LIFESCIENCES ACQUISITION CORPORATION Frazier Lifesciences Acquisition Corporation Stock
Equities
NAMS
NL00150012L7
Biotechnology & Medical Research
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 19.81 EUR | -3.37% |
|
-7.56% | +77.35% |
| May. 15 | TD Cowen Starts NewAmsterdam Pharma With Buy Rating | MT |
| May. 09 | Earnings Flash (NAMS) NEWAMSTERDAM PHARMA N.V. Reports Q1 Revenue $1.4M | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 8.45M 9.18M | Sales 2025 * | 6.3M 6.84M | Capitalization | 1.66B 1.81B |
|---|---|---|---|---|---|
| Net income 2024 * | -208M -226M | Net income 2025 * | -134M -146M | EV / Sales 2024 * | 197 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 264 x |
| P/E ratio 2024 * |
-8.01
x | P/E ratio 2025 * |
-12.8
x | Employees | 29 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.27% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | -3.37% | ||
| 1 week | -7.56% | ||
| Current month | -9.17% | ||
| 1 month | -1.20% | ||
| 3 months | -4.39% | ||
| 6 months | +109.63% | ||
| Current year | +77.35% |
1 week
19.55
22.23
1 month
19.2123.01
Current year
11.1826.35
1 year
5.6326.35
3 years
5.6332.88
5 years
5.6332.88
10 years
5.6332.88
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-17 | 20.09 | +0.20% | 145,782 |
| 24-05-16 | 20.05 | +1.21% | 188,087 |
| 24-05-15 | 19.81 | -3.37% | 244,051 |
| 24-05-14 | 20.5 | +1.43% | 134,715 |
| 24-05-13 | 20.21 | -5.69% | 107,664 |
End-of-day quote Nasdaq, May 14, 2024
More quotes
NewAmsterdam Pharma Company NV is a Netherlands based company. NewAmsterdam Pharma operates as a clinical-stage company and focuses on the research and development of transformative oral therapies for major cardiometabolic diseases. The Company is investigating obicetrapib, an oral, low-dose and once-daily, cholesteryl ester transfer protein (CETP) inhibitor, as the low-density lipoprotein cholesterol (LDL-C) lowering therapy to be used as an adjunct statin therapy for high-risk cardiovascular disease (CVD) patients. The Company is also testing obicetrapib as a fixed-dose combination therapy with ezetimibe in a secondary Phase 2 trial, ROSE2, for other diseases such as Alzheimerâs disease. The Company strives to offer its products around the world.
Calendar
2024-06-05
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
18.48
EUR
Average target price
32.11
EUR
Spread / Average Target
+73.77%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +77.35% | 1.81B | |
| +9.42% | 115B | |
| +11.84% | 106B | |
| -1.05% | 21.96B | |
| -14.15% | 21.84B | |
| -5.29% | 19.21B | |
| -4.16% | 18.08B | |
| -38.29% | 17.71B | |
| +7.99% | 14.32B | |
| +36.24% | 12.42B |
- Stock Market
- Equities
- NAMS Stock
